IPP Bureau
Lupin launches Glucagon for Injection USP, 1mg/Vial in US
By IPP Bureau - August 11, 2025
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP
By IPP Bureau - August 11, 2025
Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle
Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India
By IPP Bureau - August 11, 2025
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
SMS Pharmaceuticals reports consolidated Q1 FY26 at Rs. 20.49 Cr
By IPP Bureau - August 11, 2025
SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025
LAXAI Life Sciences appoints Sripathy Venkatraman as CEO
By IPP Bureau - August 11, 2025
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Emcure Pharmaceuticals reports Q1 FY26 consolidated PAT higher at Rs. 206.95 Cr
By IPP Bureau - August 11, 2025
Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025
Wockhardt reports Q1 FY26 loss at Rs. 108 Cr
By IPP Bureau - August 10, 2025
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
Divis Laboratories posts consolidated Q1 FY26 PAT of Rs. 545 Cr
By IPP Bureau - August 10, 2025
Divi's Laboratories has reported total income of Rs. 2,529 crores during the period ended June 30, 2025
Morepen Laboratories consolidated Q1 FY26 PAT lower at Rs. 11.40 Cr
By IPP Bureau - August 10, 2025
Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025
KIMS Q1 FY26 consolidated profit slips to Rs. 78.6 Cr
By IPP Bureau - August 10, 2025
KIMS has reported total income of Rs. 878.7 crores during the period ended June 30, 2025
Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
By IPP Bureau - August 10, 2025
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Zydus receives final approval from USFDA for Prucalopride Tablets
By IPP Bureau - August 09, 2025
Prucalopride is prescribed for chronic idiopathic constipation
Akums reports Q1 FY26 PAT at Rs. 65 Cr
By IPP Bureau - August 09, 2025
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr
By IPP Bureau - August 09, 2025
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
